Literature DB >> 30412009

Should real-world evidence be incorporated into regulatory approvals?

Ernest Spitzer1,2, Christopher P Cannon3, Patrick W Serruys4.   

Abstract

Keywords:  Pragmatic trials; randomized controlled trials; real-world data; real-world evidence

Mesh：

Year:  2018        PMID： 30412009     DOI： 10.1080/14740338.2018.1546842

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN： 1474-0338            Impact factor:   4.250


× No keyword cloud information.
  5 in total

1.  Treatment of Open-Angle Glaucoma and Ocular Hypertension with the Fixed-Dose Combination of Preservative-Free Tafluprost/Timolol: Clinical Outcomes from Ophthalmology Clinics in Italy.

Authors:  Francesco Oddone; Vincenzo Scorcia; Michele Iester; Dario Sisto; Stefano De Cilla; Paolo Bettin; Carlo Cagini; Michele Figus; Giorgio Marchini; Luca Rossetti; Gemma Rossi; Tommaso Salgarello; Gian Luca Scuderi; Giovanni Staurenghi
Journal:  Clin Ophthalmol       Date:  2022-06-01

2.  Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: UK and Ireland Results from the VISIONARY Study.

Authors:  Ejaz Ansari; Jasna Pavicic-Astalos; Filis Ayan; Anthony J King; Matthew Kinsella; Eugene Ng; Anca Nita
Journal:  Adv Ther       Date:  2021-04-22       Impact factor: 3.845

Review 3.  Real-world evidence and product development: Opportunities, challenges and risk mitigation.

Authors:  Poobalan Naidoo; Célia Bouharati; Virendra Rambiritch; Nadina Jose; Sumanth Karamchand; Robert Chilton; Rory Leisegang
Journal:  Wien Klin Wochenschr       Date:  2021-04-09       Impact factor: 1.704

4.  Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: Results from the VISIONARY Study Population in Spain.

Authors:  Jose J Garcia-Medina; Javier Benitez-Del-Castillo; Iñaki Rodríguez-Agirretxe; Fernando Lopez-Lopez; Antonio Moreno-Valladares
Journal:  J Ocul Pharmacol Ther       Date:  2022-02-28       Impact factor: 2.850

5.  Real-World Effectiveness, Tolerability and Safety of Cyclosporine A 0.1% Cationic Emulsion in Severe Keratitis and Dry Eye Treatment.

Authors:  Gerd Geerling; Samer Hamada; Stefan Trocmé; Sten Ræder; Xiangjun Chen; Claudia Fassari; Ines Lanzl
Journal:  Ophthalmol Ther       Date:  2022-03-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.